Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Carole Diane Mitnick, Sc.D.

Co-Author

This page shows the publications co-authored by Carole Mitnick and Meredith Brooks.
Connection Strength

2.800
  1. Estimating the global burden of multidrug-resistant tuberculosis among prevalent cases of tuberculosis. Int J Tuberc Lung Dis. 2017 01 01; 21(1):6-11.
    View in: PubMed
    Score: 0.346
  2. Treatment Outcomes for Adolescents With Multidrug-Resistant Tuberculosis in Lima, Peru. Glob Pediatr Health. 2016; 3:2333794X16674382.
    View in: PubMed
    Score: 0.342
  3. Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial. BMC Infect Dis. 2016 08 27; 16(1):453.
    View in: PubMed
    Score: 0.338
  4. Comparison of censoring assumptions to reduce bias in tuberculosis treatment cohort analyses. PLoS One. 2020; 15(10):e0240297.
    View in: PubMed
    Score: 0.225
  5. Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis. Am J Respir Crit Care Med. 2019 05 01; 199(9):1167-1168.
    View in: PubMed
    Score: 0.203
  6. Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study. Public Health Action. 2019 Mar 21; 9(1):32-41.
    View in: PubMed
    Score: 0.202
  7. Use of predicted vital status to improve survival analysis of multidrug-resistant tuberculosis cohorts. BMC Med Res Methodol. 2018 12 11; 18(1):166.
    View in: PubMed
    Score: 0.198
  8. Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2018 09 01; 198(5):657-666.
    View in: PubMed
    Score: 0.194
  9. Bayesian adaptive randomization in a clinical trial to identify new regimens for MDR-TB: the endTB trial. Int J Tuberc Lung Dis. 2016 12 01; 20(12):8-12.
    View in: PubMed
    Score: 0.172
  10. (Re)moving the needle: prospects for all-oral treatment for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016 12 01; 20(12):18-23.
    View in: PubMed
    Score: 0.172
  11. Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. Eur Respir J. 2016 10; 48(4):1160-1170.
    View in: PubMed
    Score: 0.169
  12. Erratum for Peloquin et al., "Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis". Antimicrob Agents Chemother. 2017 09; 61(9).
    View in: PubMed
    Score: 0.090
  13. Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. Antimicrob Agents Chemother. 2017 08; 61(8).
    View in: PubMed
    Score: 0.090
  14. Sputum culture conversion definitions and analytic practices for multidrug-resistant TB. Int J Tuberc Lung Dis. 2021 07 01; 25(7):596-598.
    View in: PubMed
    Score: 0.059
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.